Heart failure risk prediction in the Multi-Ethnic Study of Atherosclerosis

Harjit Chahal,1 David A Bluemke,2 Colin O Wu,3 Robyn McClelland,4 Kiang Liu,5 Steven J Shea,6 Gregory Burke,7 Pelbreton Balfour,8 David Herrington,8 PeiBei Shi,3 Wendy Post,1 Jean Olson,9 Karol E Watson,10 Aaron R Folsom,11 Joao A C Lima1,11

ABSTRACT

Objective Heart failure (HF) is a leading cause of mortality especially in older populations. Early detection of high-risk individuals is imperative for primary prevention. The purpose of this study was to develop a HF risk model from a population without clinical cardiac disease.

Methods The Multi-Ethnic Study of Atherosclerosis is a multicentre observational cohort study following 6814 subjects (mean age 62±10 years; 47% men) who were free of clinical cardiovascular disease at baseline. Median follow-up was 4.7 years. HF events developed in 176 participants. Cox proportional hazards models and regression coefficients were used to determine independent risk factors and generate a 5-year risk score for incident HF. Bootstraping with bias correction was used for internal validation.

Results Independent predictors for HF (HR, p value) were age (1.30 (1.10 to 1.50) per 10 years), male gender (2.27 (1.53 to 3.36)), current smoking (1.97 (1.15 to 3.36)), body mass index (1.40 (1.10 to 1.80) per 5 kg/m²), systolic blood pressure (1.10 (1.00 to 1.10) per 10 mm Hg), heart rate (1.30 (1.10 to 1.40) per 10 bpm), diabetes (2.27 (1.48 to 3.47)), N-terminal pro-B-type natriuretic peptide (NT proBNP) (2.48 (2.16 to 2.84) per unit log increment) and left ventricular mass index (1.40 (1.30 to 1.40) per 10 g/m²). A parsimonious model based on age, gender, body mass index, smoking status, systolic blood pressure, heart rate, diabetes and NT proBNP natriuretic peptide predicted incident HF risk with a c-statistic of 0.87.

Conclusions A clinical algorithm based on risk factors readily available in the primary care setting can be used to identify individuals with high likelihood of developing HF without pre-existing cardiac disease.

INTRODUCTION

Heart failure (HF) is a leading cause of morbidity and mortality in the USA and worldwide despite clinical advances made in the diagnosis and treatment of cardiovascular disease.1 It is a progressive multiorgan system disease associated with very high admission and readmission rates and ultimately shortened life expectancy in older adults.2,3 Worldwide, the incidence and prevalence of HF continues to rise due to improved life expectancy and survival from acute coronary diseases.4 Given the immense burden and healthcare costs associated with HF, the American College of Cardiology/American Heart Association (ACC/AHA) guidelines reclassified HF to include stage A which includes patients with risk factors but no structural heart disease.5

The Multi-Ethnic Study of Atherosclerosis (MESA) is a multicentre prospective cohort study designed to investigate the prevalence, correlates and progression of subclinical cardiovascular disease in community dwelling adults without previous clinical cardiovascular disease.6 In this study, we sought to determine a parsimonious risk prediction equation for use in primary care setting to identify individuals at high risk for developing HF (see online supplement).

METHODS

Study design

The study design, sampling method and data collection have been described in detail elsewhere.7 The participants of MESA were 6814 men and women aged 45–84 years old who were Caucasian, African-American, Hispanic or Chinese-American. Exclusion criteria included clinical cardiovascular disease, current atrial fibrillation, any cardiovascular procedure, pregnancy, active cancer treatment, weight >136 kg and serious medical condition that precluded long-term participation (see online supplement). The protocols of MESA were approved by the Institutional Review Boards of all collaborating institutions and the National Heart, Lung and Blood Institute and all participants signed informed consent.

Covariates

Race/ethnicity was defined by self-report during the baseline MESA exam according to 2000 US Census. Standard questionnaires were used to ascertain smoking (classified as never, former and current). Body mass index (BMI) was calculated by dividing weight in kilograms by the square of height in metres. Resting blood pressure was measured using the Dinamap Monitor PRO 100 (Critikon, Tampa, Florida, USA) automated oscillometric device. Serum glucose, total and high-density lipoprotein cholesterol were measured from blood samples after 12-h fast. The diagnosis of diabetes mellitus was based on the use of insulin or oral hypoglycaemic medication or fasting glucose ≥126 mg/dL. Impaired fasting glucose was considered present if fasting glucose was between 100–125 mg/dL. Low-density lipoprotein cholesterol...
was calculated with the Friedewald equation. Serum creatinine was measured using colorimetry with a Johnson & Johnson Vitros 900 analyser (Johnson & Johnson Clinical Diagnostics, Rochester, USA) and calibrated to the Cleveland Clinic standard. Left ventricle (LV) hypertrophy by electrocardiogram was defined using standard criteria. A subcohort of 5597 participants underwent plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) measurements. LV mass was determined by cardiac magnetic resonance imaging and indexed to body surface area. Myocardial infarction was diagnosed based on a combination of symptoms, electrocardiogram and cardiac biomarker levels. Interim myocardial infarction was defined as "newly diagnosed acute myocardial infarction during the follow-up period".

HF events
Participants were re-examined approximately every other year after the baseline examination. In addition to the study examinations, a telephone interviewer contacted each participant every 9–12 months to inquire about any hospital admissions, cardiovascular outpatient diagnoses and deaths. To verify self-reported diagnoses, copies were requested of all death certificates and medical records for all hospitalisations and outpatient cardiovascular diagnoses. Next-of-kin interviews for out-of-hospital cardiovascular deaths were obtained. We were successful in getting medical records on an estimated 98% of hospitalised cardiovascular events and information on 95% of outpatient cardiovascular diagnostic encounters. Follow-up telephone interviews were completed by 92% of living participants. Trained personnel abstracted any hospital records suggesting possible cardiovascular events and transmitted these to the coordinating centre. These were then sent to two paired physicians (cardiologists or cardiovascular physician epidemiologists) for independent end point classification and assignment of incidence dates. Persisting disagreements were classified by the full review committee. The end point for this study was a composite of probable and definite HF. Definite or probable HF required HF symptoms, such as shortness of breath or oedema. In addition to symptoms, classification of probable HF required diagnosis of HF by a physician and a receipt for medical treatment for HF. Definite HF also required one or more objective criteria, such as pulmonary oedema/congestion by chest X-ray; dilated ventricle or poor LV function by echocardiography or ventriculography; or evidence of LV diastolic dysfunction. For this analysis, we used incident definite or probable HF as a single entity without subdividing it into systolic or diastolic predominance.

Statistical analysis
For evaluating the covariate effects on time to HF during the follow-up, we treated death or loss to follow-up as censored, and considered five different Cox proportional hazards (PH) models, each with a different set of risk factors. The simplest model, Model 1, includes only the basic risk factors: age, gender, ethnicity, BMI, among others, while the subsequent models included additional variables. We evaluated the inclusion of significant covariates in the Cox PH models using least absolute shrinkage and selection operator variable selection technique. Natural log-transformations were applied to variables with skewed distributions. Hazard ratios for the development of HF and their 95% confidence intervals were computed for each of the risk factors based on their corresponding Cox PH models. In addition to the Cox PH models, we also examined the potential non-linear effects of several continuous covariates on the incidence of HF using local polynomial smoothing fits. For the variables entering the final Cox PH model, we evaluated their interactions with age, gender and ethnicity after correction for multiple testing. Internal validation of the risk prediction model was done using the bootstrap method with bias correction employing the "0.632 bootstrap". Bootstrapping is a standard method for evaluating the prediction errors of risk prediction models by comparing the prediction errors from the original sample and the bootstrap samples, which are drawn with replacement from the original sample. Since the outcome of a subject being predicted may also appear in a bootstrap sample used to construct the prediction model, the "0.632 bootstrap" is a modified bootstrap method which adjusts the potential bias by using only the bootstrap samples which do not contain the subject being predicted. As shown by various simulation and numerical studies, the "0.632 bootstrap" method has the best performance in the estimation of model prediction errors among cross-validation and different bootstrap methods. The Harrell-Pencina-D’Agostino survival c-statistics were used to compare the adequacy of different HF risk prediction models. Goodness of fit of the statistical models was assessed by the Hosmer-Lemeshow statistic. Risk reclassification for the HF risk prediction models was evaluated and compared using the net reclassification improvement (NRI) methods. For the computations of NRI, we considered the actual HF events and predicted HF probabilities based on the Cox PH models. The HF risk classification was defined to be low, intermediate, high and very high if the probability of developing HF was ≤5%, 5–10%, 10–20% and 20%, respectively, similar to risk categories used in other studies. For easy use to clinicians and patients, the results from the above models were used to create a point-based scoring system similar to the Framingham Heart Study model to generate risk estimates of HF development over a 5-year period. In brief, risk factors were organised into meaningful categories and a referential group identified. The difference between each category and the reference category in terms of regression units was computed. A constant corresponding to each unit point increase was defined. The points associated with each risk category were determined from the risk category, its reference value and the constant. The total points and associated risk were thus calculated.

RESULTS
Study population
The mean age of MESA participants at baseline was 62±10 years with 47.2% male participants; 38.5% Caucasian, 11.8% Chinese, 27.8% African-American and 22% Hispanic. Forty-five percent (45%) of MESA participants had hypertension, 12.6% had diabetes mellitus, 13.8% had impaired fasting glucose, 13% were current smokers, 32.2% were obese (BMI >30 kg/m²) and 39.2% were overweight (BMI 25–29.9 kg/m²). At baseline, 16% were on lipid lowering medication and 37% on antihypertensive therapy.

HF events
Following the baseline data collected from 2000 to 2002, we used the incident HF events that occurred subsequently during the 7.1 years of follow up. Clinical HF developed in 176 MESA participants in 4.7 years of median follow-up (range 0.1–7.0 years). Baseline demographic and risk factor characteristics of
Heart failure and cardiomyopathies

Table 1  Baseline characteristics of participants who developed HF versus those who did not develop HF at 7.1 years follow-up in MESA

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Overall (n=6814)</th>
<th>Developed HF at follow-up (n=176)</th>
<th>No HF at follow-up (n=6633)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>62.1±10</td>
<td>69.1±10*</td>
<td>62.0±10</td>
</tr>
<tr>
<td>Male (%)</td>
<td>47.1</td>
<td>60.8*</td>
<td>46.8</td>
</tr>
<tr>
<td>Caucasians (%)</td>
<td>2622 (38.5)</td>
<td>69 (39.2)</td>
<td>2533 (38.4)</td>
</tr>
<tr>
<td>Chinese-Americans (%)</td>
<td>803 (11.7)</td>
<td>9 (5.1)*</td>
<td>794 (12.0)</td>
</tr>
<tr>
<td>African-Americans (%)</td>
<td>1892 (27.8)</td>
<td>59 (33.5)*</td>
<td>1833 (27.6)</td>
</tr>
<tr>
<td>Hispanics (%)</td>
<td>1496 (22.0)</td>
<td>39 (22.0)*</td>
<td>1457 (22.0)</td>
</tr>
<tr>
<td>Systolic blood pressure (mm Hg)</td>
<td>126.6±21.5</td>
<td>140.4±22.4*</td>
<td>126.2±21.3</td>
</tr>
<tr>
<td>Diastolic blood pressure (mm Hg)</td>
<td>71.9±10.3</td>
<td>73.9±10.8*</td>
<td>71.9±10.2</td>
</tr>
<tr>
<td>Heart rate (bpm)</td>
<td>63±10</td>
<td>65.0±11.1*</td>
<td>63.1±9.6</td>
</tr>
<tr>
<td>Total cholesterol (mg/dL)</td>
<td>194±35.7</td>
<td>189.6±35.1*</td>
<td>194.3±35.1</td>
</tr>
<tr>
<td>HDL cholesterol (mg/dL)</td>
<td>51±15</td>
<td>47.9±14.1*</td>
<td>51.1±14.8</td>
</tr>
<tr>
<td>Hypertension (%)</td>
<td>44.9</td>
<td>75.6*</td>
<td>44.1</td>
</tr>
<tr>
<td>Hypertension medication (%)</td>
<td>37.2</td>
<td>63.1*</td>
<td>36.5</td>
</tr>
<tr>
<td>Diabetes mellitus (%)</td>
<td>12.6</td>
<td>31.8*</td>
<td>12.1</td>
</tr>
<tr>
<td>Current cigarette smokers (%)</td>
<td>13.0</td>
<td>16.5*</td>
<td>12.9</td>
</tr>
<tr>
<td>Pack years</td>
<td>11.4±22.3</td>
<td>18.3±30.9*</td>
<td>11.2±22.0</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>28.3±5.5</td>
<td>30.1*</td>
<td>28.3</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>0.96±0.3</td>
<td>1.1±0.7*</td>
<td>0.9±0.3</td>
</tr>
<tr>
<td>ECG-LVH (%)</td>
<td>1.0</td>
<td>6.3*</td>
<td>0.9</td>
</tr>
<tr>
<td>LV mass index (g/m²)</td>
<td>77.9±16.3</td>
<td>96.7*</td>
<td>77.5</td>
</tr>
<tr>
<td>NT-proBNP (pg/mL)</td>
<td>102.3±249.7</td>
<td>456.4*</td>
<td>93.0</td>
</tr>
</tbody>
</table>

Parentheses represent units of measurements with the respective 95% CIs or percentages as appropriate.

*p<0.05 for difference

†vs Caucasians.

BMI, body mass index; ECG, electrocardiogram; HDL, high-density lipoprotein; HF, heart failure; LVH, LV hypertrophy; MESA, Multi-Ethnic Study of Atherosclerosis; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

the study participants stratified by incident HF are presented in table 1. Participants who developed HF were more likely at baseline to be elderly, male, African-American, hypertensive, diabetic, current smokers and had higher BMI, LV mass index and NT-proBNP.

Risk factors for prediction of incident HF

Results from the Cox PH models for incident HF are presented in table 2. Significant independent predictors in the basic model (model 1) were age, male gender, smoking status, BMI, systolic blood pressure, heart rate, diabetes mellitus and creatinine.

Table 2  HRs (95% CIs) associating risk factors with incident HF events in MESA

<table>
<thead>
<tr>
<th>Models (n)</th>
<th>Model 1 (6678)</th>
<th>Model 2 (6678)</th>
<th>Model 3 (5504)</th>
<th>Model 4a (6678)</th>
<th>Model 4b (4912)</th>
<th>Model 5 (4904)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (per year increment)</td>
<td>1.071 (1.05 to 1.09)</td>
<td>1.081 (1.05 to 1.10)</td>
<td>1.034 (1.0 to 1.05)</td>
<td>1.074 (1.05 to 1.09)</td>
<td>1.01 (1.03 to 1.08)</td>
<td>–</td>
</tr>
<tr>
<td>Gender (male vs female)</td>
<td>1.641 (1.15 to 2.34)</td>
<td>2.08 (1.45 to 2.99)</td>
<td>2.271 (1.53 to 3.36)</td>
<td>1.551 (1.09 to 2.22)</td>
<td>1.101 (0.68 to 1.77)</td>
<td>1.361 (0.78 to 2.36)</td>
</tr>
<tr>
<td>Cigarette smoking (current vs never)</td>
<td>2.351 (1.49 to 3.71)</td>
<td>2.981 (1.87 to 4.76)</td>
<td>1.971 (1.15 to 3.36)</td>
<td>2.401 (1.54 to 3.81)</td>
<td>1.981 (1.13 to 3.46)</td>
<td>2.541 (1.36 to 4.74)</td>
</tr>
<tr>
<td>BMI (per kg/m² increment)</td>
<td>1.051 (1.02 to 1.09)</td>
<td>1.081 (1.04 to 1.11)</td>
<td>1.041 (1.0 to 1.05)</td>
<td>1.051 (1.02 to 1.08)</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>Systolic BP (per mm Hg)</td>
<td>1.011 (1.00 to 1.02)</td>
<td>1.011 (1.00 to 1.02)</td>
<td>1.011 (1.00 to 1.02)</td>
<td>1.021 (1.00 to 1.02)</td>
<td>1.001 (0.99 to 1.01)</td>
<td>1.001 (0.99 to 1.01)</td>
</tr>
<tr>
<td>Heart rate (per beat/min)</td>
<td>1.031 (1.00 to 1.03)</td>
<td>1.01 (1.00 to 1.03)</td>
<td>1.031 (1.00 to 1.04)</td>
<td>1.021 (1.00 to 1.03)</td>
<td>1.031 (1.01 to 1.05)</td>
<td>1.041 (1.02 to 1.06)</td>
</tr>
<tr>
<td>Diabetes (vs non-diabetics)</td>
<td>2.341 (1.62 to 3.37)</td>
<td>1.831 (1.25 to 2.68)</td>
<td>2.271 (1.48 to 3.47)</td>
<td>2.301 (1.60 to 3.32)</td>
<td>2.581 (1.60 to 4.16)</td>
<td>1.851 (1.05 to 3.28)</td>
</tr>
<tr>
<td>Creatine (per mg/dL)</td>
<td>1.401 (1.16 to 1.70)</td>
<td>0.941 (0.78 to 1.18)</td>
<td>–</td>
<td>1.421 (1.18 to 1.71)</td>
<td>1.281 (1.04 to 1.57)</td>
<td>–</td>
</tr>
<tr>
<td>NT-proBNP (per log unit increment)</td>
<td>–</td>
<td>2.481 (2.16 to 2.84)</td>
<td>–</td>
<td>–</td>
<td>1.621 (1.35 to 1.95)</td>
<td>–</td>
</tr>
<tr>
<td>ECG-LVH (vs no LVH)</td>
<td>–</td>
<td>–</td>
<td>4.161 (2.20 to 7.85)</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>LV mass index (per unit g/m² increment)</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>1.041 (1.03 to 1.04)</td>
<td>1.021 (1.01 to 1.03)</td>
<td>–</td>
</tr>
</tbody>
</table>

1p<0.001, 2p<0.01, 3p<0.05.

Significant HR and their confidence intervals are presented in bold.

Model 1: includes age, gender, ethnicity, BMI, cigarette smoking, systolic blood pressure, heart rate, diabetes mellitus, total cholesterol, HDL cholesterol and creatinine.

Model 2: Model 1+ interim myocardial infarction.

Model 3: age, gender, ethnicity, BMI, cigarette smoking, systolic blood pressure, heart rate, diabetes mellitus, total cholesterol, HDL cholesterol and log of NT-proBNP.

Model 4a: age, gender, ethnicity, BMI, cigarette smoking, systolic blood pressure, heart rate, diabetes mellitus, creatinine, total cholesterol, HDL cholesterol and ECG-LVH.

Model 4b: age, gender, ethnicity, cigarette smoking, systolic blood pressure, heart rate, diabetes mellitus, creatinine and LV mass indexed to body surface area.

Model 5: age, gender, ethnicity, cigarette smoking, systolic blood pressure, heart rate, diabetes mellitus, interim myocardial infarction, LV mass indexed to body surface area and log of NT-proBNP.

BMI, body mass index; HF, heart failure; LVH, LV hypertrophy; MESA, Multi-Ethnic Study of Atherosclerosis; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
Harrell’s c-statistic for the basic model was 0.80. C-statistic represents the ability of the score to discriminate future events from non-events. In this case a c-statistic of 0.80 indicates that a randomly selected HF event has a higher score than a randomly selected non-event 80% of the time. Model 2 was adjusted for interim myocardial infarction. In model 3, we added log transformed NT-proBNP. Given the collinearity between NT-proBNP and creatine, they were not included in the same model. The statistical associations between risk factors from the base model persisted even after the addition of log NT-proBNP with substantial improvement of c-statistic to 0.87. When LV mass index was added to the model (model 4b), gender and systolic blood pressure became non-significant; c-statistic for this model was 0.85. When Left ventricle (LV) hypertrophy by electrocardiogram hypertrophy (model 4a) was used instead of LV mass index, the c-statistic was only marginally higher than the basic model (0.81). For model containing all significant risk predictors (model 5) the c-statistic was 0.91 with age, smoking, heart rate, diabetes, interim myocardial infarction, log NT-proBNP and LV mass index retaining independent statistical significance.

The associations between incident HF and systolic blood pressure, heart rate and LV mass index were non-linear (online supplementary figures 1 and 2). Significant interactions were present for gender by heart rate and LV mass index by ethnicity. For a unit increment in heart rate, women had higher risk for HF than men (HR 1.03 vs 1.01; p for the interaction term, p=0.004). For a unit increment in LV mass index, the risk for HF in African-Americans was lower than in Caucasians (HR 1.03 vs 1.05 per g/m2; p=0.002).

We assessed the reclassification value of log NT-proBNP and LV mass index beyond the known risk predictors of HF, including demographics and traditional risk factors (table 3). NRI estimates improved with the addition of log NT-proBNP and LV mass index to traditional risk factors primarily due to upward reclassification of individuals who subsequently developed HF (online supplement 2–5). When LV mass index was added to the model containing traditional risk factors and log NT-proBNP, the NRI estimate for the low, intermediate and high categories was non-significant. Conversely, the addition of log NT-proBNP improved the NRI beyond LV mass index for the three risk categories.

A point based scoring system was used to develop a method for calculating an associated 5-year HF risk based on age, gender, BMI, smoking status, systolic blood pressure, heart rate, diabetes and NT pro-BNP (tables 4 and 5). Addition of NT-proBNP improved the net reclassification index by 0.37. The distribution of expected versus observed HF incidence across deciles of risk is shown in figure 1.

**Table 4** Point scoring for calculation of risk factor profile

<table>
<thead>
<tr>
<th>Risk factor</th>
<th>Categories</th>
<th>Points</th>
<th>NRI</th>
<th>p value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>45–54</td>
<td>0</td>
<td>&lt;120</td>
<td>0</td>
</tr>
<tr>
<td>55–64</td>
<td>2</td>
<td>120–139</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>65–74</td>
<td>4</td>
<td>140–159</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>75–84</td>
<td>6</td>
<td>≥160</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td>Female</td>
<td>Heart rate</td>
<td>&lt;60</td>
<td>-1</td>
</tr>
<tr>
<td>Male</td>
<td></td>
<td>60–69</td>
<td>0</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>70–79</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>80–89</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥90</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>Smoker</td>
<td>Never</td>
<td>Diabetes</td>
<td>normal</td>
<td>0</td>
</tr>
<tr>
<td>Former</td>
<td></td>
<td>IFG</td>
<td>1</td>
<td></td>
</tr>
<tr>
<td>Current</td>
<td>2</td>
<td>Diabetes</td>
<td>2</td>
<td></td>
</tr>
<tr>
<td>BMI</td>
<td>Normal</td>
<td>NT pro-BNP</td>
<td>&lt;200 pg/mL</td>
<td>0</td>
</tr>
<tr>
<td>Overweight</td>
<td></td>
<td>200–400 pg/mL</td>
<td>4</td>
<td></td>
</tr>
<tr>
<td>BMI Obese</td>
<td>1</td>
<td>400–600 pg/mL</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>600–800 pg/mL</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td>≥800 pg/mL</td>
<td>11</td>
<td></td>
</tr>
</tbody>
</table>

BMI, body mass index; SBP, systolic blood pressure; IFG, impaired fasting glucose; NT-proBNP, N-terminal pro-B-type natriuretic peptide.

**Table 5** MESA 5-year HF risk score

<table>
<thead>
<tr>
<th>Cumulative points</th>
<th>HF risk group</th>
<th>5-year HF risk (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>≤9 points</td>
<td>Low</td>
<td>&lt;5</td>
</tr>
<tr>
<td>10–12 points</td>
<td>Average</td>
<td>5–10%</td>
</tr>
<tr>
<td>12–14 points</td>
<td>High</td>
<td>10–20%</td>
</tr>
<tr>
<td>≥15 points</td>
<td>Very high</td>
<td>&gt;20%</td>
</tr>
</tbody>
</table>

HF, heart failure; MESA, Multi-Ethnic Study of Atherosclerosis.
Heart failure and cardiomyopathies

Figure 1  Quintile plots for observed versus predicted risk.

Predictors of HF. In the present study, the addition of log NT-proBNP produced the largest increase in the c-statistic from the base model. Furthermore, although LV mass was an independent predictor of HF in all models (including log NT-proBNP); it did not represent a significant risk reclassifier over and above NT-proBNP. On the other hand, NT-proBNP significantly improved the reclassification over LV mass. Therefore we selected NT-proBNP over imaging parameters for the final risk prediction equation.

Risk assessment is the key in the field of cardiovascular disease prevention. In clinical practice, risk prediction algorithms have been used to identify high-risk individuals for more intensive preventive and therapeutic interventions. The MESA HF risk assessment model builds upon the risk evaluation intensive preventive and therapeutic interventions. The MESA algorithms have been used to identify high-risk individuals for more disease prevention. In clinical practice, risk prediction algorithms have been applied. A score derived from populations that included pre-existing cardiovascular disease risk factors is highly dependent on the population from which it is derived; as well as the population to which it is applied. A score derived from populations that included presence of clinical heart disease at study onset may not be as useful to identify ACC/AHA stage A or stage B HF in populations of healthier individuals. In the Health ABC study, the risk calculator was derived from a healthier cohort of older adults without pre-existing cardiovascular disease, but that study did not include NT-proBNP, which in MESA and ARIC provided the largest contribution to risk assessment. The MESA study demonstrates a strong predictive model in a multiethnic population without pre-existing clinical cardiac disease that should be used to predict incident HF for primary prevention.

The use of the MESA risk assessment profile based on routine labs could facilitate identification of patients at highest risk levels in whom further testing and aggressive risk reduction could be beneficial. The risk factors included in our study are easily available in primary care settings and some are potentially modifiable. The present study also alludes to certain gender and ethnic differences in relation to risk factors and development of HF. The associations of risk factors with HF were similar across different age, ethnicity and gender groups except heart rate which showed a stronger risk for HF in women as compared with men; and LV mass index which showed a lower risk of HF in African-Americans as compared with Caucasians. Although beyond the scope of this study, such subtle findings could mean differential pathophysiology and/or remodelling in different sub-groups in relationship to these risk factors which could be a focus for more specific risk reduction strategies.

Strengths of MESA include high quality assessment of risk markers such as LV mass using magnetic resonance imaging, and the measurement of multiple risk factors including biomarkers which are responsible for a high predictive value of the MESA score. MESA HF events included inpatient and outpatient diagnoses further reviewed and verified by a MESA cardiologist. The MESA population includes a substantial proportion of previously understudied ethnic groups and is derived from diverse geographical locations in the USA.

Key messages

What is already known on this subject?
Heart failure (HF) continues to be the leading cause of morbidity and mortality with enormous economic burden globally. Several epidemiological studies have identified cardiac (hypertension, diabetes, obesity, smoking, etc.) and non-cardiac (albumin, renal function, C reactive protein, etc.) risk factors associated which are associated with the development of HF. Major cohort studies including the older Framingham study and the more recent Atherosclerosis Risk in Communities and the Health ABC studies have devised risk prediction algorithms based on several risk markers to predict future risk of HF.

What might this study add?
In this study which is derived from the Multi-Ethnic Study of Atherosclerosis (MESA) we developed a point based scoring system for estimating the risk of developing HF based on common risk factors which can be easily available in the primary care setting. We believe that this ‘MESA HF-risk score’ will be helpful to primary care clinicians and cardiologists to identify and focus on patients that do not have cardiac disease at present, but are at high risk of developing HF in the future.

How might this impact on clinical practice?
Given the high burden, mortality and morbidity associated with HF, experts have recommended greater focus on prevention. Application of a risk prediction tool by clinicians can help motivate patients and physicians to aggressively target modifiable risk factors.
Heart failure and cardiomyopathies

There are several limitations to our study that deserve discussion. The number of HF events was lower compared with other cohorts primarily due to the younger age of this population. Chinese-American participants had the lowest number of events, making it difficult to derive meaningful associations in this ethnic group. HF was not differentiated into systolic and diastolic HF due to the limited power for subanalysis given the low number of events. Risk factors were measured only at baseline, hence temporal and causal inferences cannot be made from this study alone. Although the ethnic diversity is a unique strength of our study, the MESA population does not represent all ethnic groups. Furthermore, it must be noted that although one of the strengths of MESA is its ethnic diversity and that ethnic differences in HF are well known; ethnicity was not significant in the final model and though available readily at the bedside does not contribute to predicting HF risk in a community population. Lastly, residual confounding cannot be completely eliminated from epidemiological studies.

In conclusion, we derived a robust HF risk estimation tool using clinical and ancillary variables that are partly modifiable and could be targeted for preventive strategies. Future clinical trials designed to examine the effectiveness of HF risk reduction strategies based on this predictive model are warranted.

**Author affiliations**

1Department of Cardiology, Johns Hopkins University, Baltimore, Maryland, USA
2Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda, Maryland, USA
3Department of Preventive Medicine, Northwestern University Medical School, Chicago, Illinois, USA
4Department of Epidemiology, Columbia University, New York, New York, USA
5Department of Public Health Sciences, Wake Forest University, Winston-Salem, North Carolina, USA
6Department of Cardiology, Wake Forest University, Winston-Salem, North Carolina, USA
7Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
8Division of Epidemiology, Columbia University, New York, New York, USA
9Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, USA
10Division of Cardiology, Wake Forest University, Winston-Salem, North Carolina, USA
11Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
12Division of Preventive Medicine and Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
13Department of Cardiology, UCLA-School of Medicine, Los Angeles, California, USA
14Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, USA
15Division of Health Research, Kaiser Permanente Northwest, Portland, Oregon, USA
16Department of Preventive Medicine and Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
17Division of Cardiology, UCLA-School of Medicine, Los Angeles, California, USA
18Department of Preventive Medicine, Northwestern University Medical School, Chicago, Illinois, USA
19Department of Epidemiology, Harvard School of Public Health, Boston, Massachusetts, USA
20Department of Epidemiology, Columbia University, New York, New York, USA
21Division of Epidemiology, Columbia University, New York, New York, USA

**Contributors**

JACL is the guarantor of the entire manuscript. HC: contributed to study concept and design, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. KEW: contributed to study concept and design, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. KEM: contributed to study concept and design, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. ARF: contributed to acquisition and interpretation of MRI data, study concept and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content. JACL: contributed to acquisition and interpretation of MRI data, study concept and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.

**Competing interests**

HC, DAB, COW, RM, KL, SJS, GB, PB, DH, PS, WP, JO, KEW, ARF and JACL have reported that no potential conflicts of interest exist with any companies/organisations whose products or services may be discussed in this article. This manuscript was reviewed by MESA investigators for scientific content and consistency of data interpretation with previous MESA publications, and significant comments were incorporated before submission for publication. The authors thank the other investigators, staff, and participants of the MESA studies for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org.

**Funding**

The Multi-Ethnic Study of Atherosclerosis is sponsored by contracts from the National Heart and Lung Institute (N01-HC-95165 through N01-HC-95166 and N01-HC95169).

**Contributors**

1Department of Cardiology, Johns Hopkins University, Baltimore, Maryland, USA
2Department of Radiology and Imaging Sciences, National Institutes of Health, Bethesda, Maryland, USA
3Department of Preventive Medicine, Northwestern University Medical School, Chicago, Illinois, USA
4Department of Epidemiology, Columbia University, New York, New York, USA
5Department of Public Health Sciences, Wake Forest University, Winston-Salem, North Carolina, USA
6Department of Cardiology, Wake Forest University, Winston-Salem, North Carolina, USA
7Division of Prevention and Population Sciences, National Heart, Lung, and Blood Institute, Bethesda, Maryland, USA
8Division of Epidemiology, UCLA-School of Medicine, Los Angeles, California, USA
9Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, USA
10Division of Cardiology, Wake Forest University, Winston-Salem, North Carolina, USA
11Division of Cardiovascular Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA
12Division of Preventive Medicine and Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA
13Department of Cardiology, UCLA-School of Medicine, Los Angeles, California, USA
14Division of Epidemiology, Columbia University, New York, New York, USA
15Division of Epidemiology and Community Health, University of Minnesota, Minneapolis, Minnesota, USA
16Department of Preventive Medicine, Northwestern University Medical School, Chicago, Illinois, USA
17Department of Epidemiology, Columbia University, New York, New York, USA
18Department of Epidemiology, Columbia University, New York, New York, USA

**Contributors**

JACL is the guarantor of the entire manuscript. HC: contributed to study concept and design, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content, and takes responsibility for the integrity of the work as a whole. DAB: contributed to acquisition and interpretation of MRI data, study concept and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content. JACL: contributed to acquisition and interpretation of MRI data, study concept and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content. KEW: contributed to study concept and design, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. KEM: contributed to study concept and design, analysis and interpretation of data, drafting of the manuscript, and critical revision of the manuscript for important intellectual content. ARF: contributed to acquisition and interpretation of MRI data, study concept and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content. JACL: contributed to acquisition and interpretation of MRI data, study concept and design, analysis and interpretation of data, and critical revision of the manuscript for important intellectual content.

**Competing interests**

HC, DAB, COW, RM, KL, SJS, GB, PB, DH, PS, WP, JO, KEW, ARF and JACL have reported that no potential conflicts of interest exist with any companies/organisations whose products or services may be discussed in this article. This manuscript was reviewed by MESA investigators for scientific content and consistency of data interpretation with previous MESA publications, and significant comments were incorporated before submission for publication. The authors thank the other investigators, staff, and participants of the MESA studies for their valuable contributions. A full list of participating MESA investigators and institutions can be found at http://www.mesa-nhlbi.org.

**Ethics approval**

Institutional Review Boards of all collaborating institutions and the National Heart, Lung and Blood Institute (NHLBI).

**Provenance and peer review**

Not commissioned; externally peer reviewed.

**Data sharing statement**

The corresponding author has the right to grant on behalf of all authors and does grant on behalf of all authors, an exclusive license (or non-exclusive for government employees) on a worldwide basis to the BMJ Publishing Group and its licensees to permit this article (if accepted) to be published in *Heart* editions and any other Bmj products to exploit all subsidiary rights.

**REFERENCES**

Heart failure and cardiomyopathies


